GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Anixa Biosciences Inc (NAS:ANIX) » Definitions » Price-to-Owner-Earnings

Anixa Biosciences (Anixa Biosciences) Price-to-Owner-Earnings : (As of Jun. 08, 2024)


View and export this data going back to 1989. Start your Free Trial

What is Anixa Biosciences Price-to-Owner-Earnings?

As of today (2024-06-08), Anixa Biosciences's share price is $2.55. Anixa Biosciences does not have enough data to calculate Owner Earnings per Share (TTM), so as pPrice-to-Owner-Earnings.


The historical rank and industry rank for Anixa Biosciences's Price-to-Owner-Earnings or its related term are showing as below:


ANIX's Price-to-Owner-Earnings is not ranked *
in the Biotechnology industry.
Industry Median: 33.7
* Ranked among companies with meaningful Price-to-Owner-Earnings only.

As of today (2024-06-08), Anixa Biosciences's share price is $2.55. Anixa Biosciences's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Apr. 2024 was $-0.37. Therefore, Anixa Biosciences's PE Ratio for today is At Loss.

As of today (2024-06-08), Anixa Biosciences's share price is $2.55. Anixa Biosciences's EPS without NRI for the trailing twelve months (TTM) ended in was $-0.37. Therefore, Anixa Biosciences's PE Ratio without NRI for today is At Loss.


Anixa Biosciences Price-to-Owner-Earnings Historical Data

The historical data trend for Anixa Biosciences's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Anixa Biosciences Price-to-Owner-Earnings Chart

Anixa Biosciences Annual Data
Trend Oct14 Oct15 Oct16 Oct17 Oct18 Oct19 Oct20 Oct21 Oct22 Oct23
Price-to-Owner-Earnings
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Anixa Biosciences Quarterly Data
Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24
Price-to-Owner-Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Anixa Biosciences's Price-to-Owner-Earnings

For the Biotechnology subindustry, Anixa Biosciences's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Anixa Biosciences's Price-to-Owner-Earnings Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Anixa Biosciences's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Anixa Biosciences's Price-to-Owner-Earnings falls into.



Anixa Biosciences Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Anixa Biosciences's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=2.55/-0.39
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Anixa Biosciences  (NAS:ANIX) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


Anixa Biosciences Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of Anixa Biosciences's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


Anixa Biosciences (Anixa Biosciences) Business Description

Traded in Other Exchanges
N/A
Address
3150 Almaden Expressway, Suite 250, San Jose, CA, USA, 95118
Anixa Biosciences Inc, a cancer-focused biotechnology company, developing vaccines and therapies that are focused on critical unmet needs in oncology. The company is developing both diagnostics and therapeutics to detect cancer early, which is curable, and to treat those afflicted once diagnosed. Its segment includes CAR-T Therapeutics; Cancer Vaccines; Anti-Viral Therapeutics and others.
Executives
Amit Kumar director, officer: Chief Executive Officer C/O ACACIA RESEARCH CORPORATION, 500 NEWPORT CENTER DRIVE, 7TH FLOOR, NEWPORT BEACH CA 92660
Michael Catelani officer: COO & CFO 12100 WILSHIRE BOULEVARD, SUITE 1275, LOS ANGELES CA 90025
Titterton Lewis H Jr director 6 AUTUMN LANE, SARATOGA SPRINGS NY 12866
Arnold M Baskies director 1235 SEQUOIA ROAD, CHERRY HILL NJ 08003
Emily Gottschalk director 3150 ALMADEN EXPRESSWAY, SUITE 250, SAN JOSE CA 95118
John J Monahan director
David Cavalier director C/O AEOLUS PHARMACEUTICALS, INC., 23811 INVERNESS PLACE, LAGUNA NIGUEL CA 92677
Richard H Williams director C/O QUOKKA SPORTS INC, 525 BRANNAN ST GROUND FL, SAN FRANCISCO CA 94108
Dale Fox director 929 NOWITA PLACE, VENICE CA 90291
Andrea Belz director 1011 ALTA VISTA DRIVE, ALTADENA CA 91001
Tisha Stender officer: Chief Operating Officer 900 WALT WHITMAN ROAD, MELVILLE NY 11747
Robert Andrew Berman officer: President and CEO C/O ITUS CORPORATION, 12100 WILSHIRE BOULEVARD, SUITE 1275, LOS ANGELES CA 90025
John H. Roop officer: Sr. Vice President-Engineering C/O COPYTELE, INC., 900 WALT WHITMAN ROAD, MELVILLE NY 11747
Bruce F Johnson director 20 S. WACKER DR, CHICAGO IL 60606
Kent B. Williams director C/O COPYTELE INC., 900 WALT WHITMAN ROAD, MELVILLE NY 11747